U.S. Markets closed

Genmab A/S (GNMSF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
222.00-3.00 (-1.33%)
At close: 12:10PM EDT
Full screen
Previous Close225.00
Open222.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range222.00 - 222.00
52 Week Range158.25 - 239.75
Volume1,120
Avg. Volume128
Market Cap13.66B
Beta0.30
PE Ratio (TTM)64.50
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : September 18, 2017
    Capital Cube7 days ago

    Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : September 18, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Genmab A/S. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Genmab A/S :GNMSF-US: Earnings Analysis: Q2, 2017 By the Numbers : September 12, 2017
    Capital Cube13 days ago

    Genmab A/S :GNMSF-US: Earnings Analysis: Q2, 2017 By the Numbers : September 12, 2017

    Categories: Yahoo FinanceGet free summary analysis Genmab A/S reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Genmab A/S – Agenus Inc., Lexicon Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc. and OncoMed Pharmaceuticals, Inc. (AGEN-US, LXRX-US, IONS-US and OMED-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)

  • Genmab A/S – Value Analysis (US OTC:GNMSF) : August 21, 2017
    Capital Cubelast month

    Genmab A/S – Value Analysis (US OTC:GNMSF) : August 21, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Genmab A/S a score of 82. Our analysis is based on comparing Genmab A/S with the following peers – Agenus Inc., Lexicon Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc. and OncoMed Pharmaceuticals, Inc. (AGEN-US, LXRX-US, IONS-US and OMED-US). Investment Outlook Genmab A/S has a fundamental score of 82 and ... Read more (Read more...)